摘要
目的观察倍他乐克治疗慢性心衰(CHF)的临床疗效及安全性。方法将160例CHF患者随机分为治疗组(80例)和对照组(80例),治疗组在常规抗心衰治疗基础上加用倍他乐克;对照组给予常规抗心衰治疗,并进行18个月门诊随访观察。结果治疗组治疗后其疗效、超声指标、24小时动态ECG、6分钟步行距离均较对照组有明显改善(P<0.05),治疗组的再次住院率和死亡率明显低于对照组(P<0.01)。结论倍他乐克对慢性心衰的治疗有显著效果。
Objective To observe the efficacy and safety of metoprolol for the patients with chronic heart failure （CHF）, Methods One hundred and sixty patients with chronic heart failure were randomly assigned to control group （ n = 80） and treatment group （ n = 80 ）. The control group received routine CHF treatment while the treatment group received additionally metoprolol. The development of CHF was observed for 18 months. Results There were a significant improvement in echocardiography, 24h dynamic ECG and the distance for 6 minutes walking test in the treated group as compared with the comparative group （ P 〈 0.05 ）. The rate of rehospitalization and mortality rate were lower markedly than that in the control group （P 〈 0.01 ）. Conclusions Metoprolol is a medicine of high efficacy on the chronic heart failure.
出处
《实用全科医学》
2008年第2期119-120,共2页
Applied Journal Of General Practice
关键词
慢性心衰
倍他乐克
Chronic heart failure
Betaloc
